(Q41749098)

8 October 2017

1 reference

title

Ranolazine: a novel metabolic modulator for the treatment of angina (English)

1 reference

8 October 2017

McCormack JG

1

1 reference

8 October 2017

Stanley WC

series ordinal

2

1 reference

8 October 2017

Wolff AA

series ordinal

3

1 reference

8 October 2017

publication date

1 May 1998

1 reference

8 October 2017

1 reference

8 October 2017

volume

30

1 reference

8 October 2017

issue

5

1 reference

8 October 2017

page(s)

639-645

1 reference

Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction.

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Metabolic management of ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

On the roles of long-chain acyl carnitine accumulation and impaired glucose utilization in ischaemic contracture development and tissue damage in the guinea-pig heart

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Protective Effects of Ranolazine on Ventricular Fibrillation Induced by Activation of the ATP-Dependent Potassium Channel in the Rabbit Heart

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Ranolazine--a new drug with beneficial effects on renal preservation

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Regulation of fatty acid oxidation in the mammalian heart in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Role of calcium ions in regulation of mammalian intramitochondrial metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Fuel selection in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Energy metabolism of the heart: from basic concepts to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

The 2-oxo acid dehydrogenase complexes: recent advances

1 reference

https://api.crossref.org/works/10.1016%2FS0306-3623%2897%2900301-7

7 January 2021

10.1016/S0306-3623(97)00301-7

Identifiers

DOI

1 reference

8 October 2017

1 reference